ADAR1 Capital Management LLC Has $4.86 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

ADAR1 Capital Management LLC increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 463.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 40,002 shares of the biotechnology company's stock after acquiring an additional 32,902 shares during the quarter. Sarepta Therapeutics makes up 1.0% of ADAR1 Capital Management LLC's holdings, making the stock its 25th largest holding. ADAR1 Capital Management LLC's holdings in Sarepta Therapeutics were worth $4,864,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Sarepta Therapeutics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock worth $1,104,701,000 after purchasing an additional 117,904 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after buying an additional 665,087 shares during the period. Geode Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company's stock valued at $207,538,000 after buying an additional 9,999 shares in the last quarter. Norges Bank purchased a new position in shares of Sarepta Therapeutics during the fourth quarter valued at $126,315,000. Finally, Erste Asset Management GmbH raised its position in Sarepta Therapeutics by 11.3% during the fourth quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company's stock valued at $86,116,000 after buying an additional 72,183 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 7.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft dropped their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a report on Wednesday, March 19th. Cantor Fitzgerald restated an "overweight" rating and set a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their price objective for the company from $161.00 to $87.00 in a research note on Monday, March 31st. HC Wainwright raised shares of Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 target price on the stock in a research report on Wednesday, April 2nd. Finally, Scotiabank reduced their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $161.83.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock traded up $0.72 during trading hours on Friday, hitting $51.03. The stock had a trading volume of 4,036,516 shares, compared to its average volume of 1,385,946. Sarepta Therapeutics, Inc. has a fifty-two week low of $48.01 and a fifty-two week high of $173.25. The company has a market cap of $4.95 billion, a PE ratio of 40.82 and a beta of 0.93. The company has a 50-day moving average of $88.11 and a two-hundred day moving average of $110.20. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.